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Sir,
Staphylococcus pseudintermedius is one of the most common
pathogens isolated from skin and post-operative infections in
dogs and cats1,2 and can also occasionally cause infections in
humans.3,4 People working or living with animals are more
likely to be colonized with S. pseudintermedius in their nasal cav-
ities5 and human infection acquired from dogs has been recently
reported.4 In recent years, there have been increasing numbers
of infections in dogs and cats caused by methicillin-resistant
S. pseudintermedius (MRSP) and a predominant MRSP clone is
disseminating in dogs and cats throughout Europe.1,2 This
MRSP clone belongs to the multilocus sequence type (MLST)
ST71, spa type t02 and SmaI PFGE group J (ST71-t02-J) and con-
tains the staphylococcal cassette chromosome element SCCmec
II–III.1 It displays resistance to many classes of antibiotics and
represents a challenge for therapy. Here, we report, to our knowl-
edge, the first case of a human infection caused by MRSP ST71
emphasizing its zoonotic potential and therapeutic challenge.
An adult patient presented to the doctor in 2009 with
headache, watery eyes and a small oedema over the right eye.
The patient had a history of recurrent rhinosinusitis and three
surgical interventions had been performed over the previous 6
years, the last one in 2005. CT illustrated an obliteration of the
right sinus frontalis with an expansive mucocele. Yet another sur-
gical intervention was absolutely essential and post-operative
treatment for 3 weeks with 500 mg of ciprofloxacin twice per
day and 300 mg of clindamycin three times per day was given.
Five weeks post-operatively, a purulent infection appeared.
After 10 days of treatment with 875 mg of amoxicillin/125 mg
of clavulanic acid twice daily and 300 mg of clindamycin three
times daily and no improvement, a sample was sent for bacterio-
logical analysis. The laboratory identified a multidrug-resistant
Table 1. MICs of 22 antibiotics and antibiotic resistance genes in S. pseudintermedius ST71, strain 27366
Antibiotics Resistance breakpointsa (mg/L) MICs (mg/L) Resistance genes
Amikacin ≥64 ≤16 —
Amoxicillin/clavulanic acid ≥8/4 8/4 mecA
Cefalotin ≥32 32 mecA
Chloramphenicol ≥32 8 —
Clindamycin ≥4 .8 erm(B)
Enrofloxacin ≥4 .16 grlA (Ser80Ile); gyrA (Ser84Leu)
Erythromycin ≥8 .16 erm(B)
Fusidic acid NA ≤0.12 —
Gentamicin ≥16 16 aac(6′)-Ie-aph(2)-Ia
Kanamycin ≥64 .128 aph(3′)-III
Linezolid ≥8 ≤1 —
Mupirocin NA ≤4 —
Nitrofurantoin ≥128 ≤16 —
Oxacillin ≥0.5b .8 mecA
Penicillin ≥0.25 8 blaZ; mecA
Quinupristin/dalfopristin ≥4 1 —
Rifampicin ≥4 ≤0.12 —
Streptomycin ≥32 .32 ant(6)-Ia
Tetracycline ≥16 .32 tet(K)
Trimethoprim/sulfamethoxazole ≥4/76 .8/152 dfr(G)/ND
Trimethoprim ≥16 .128 dfr(G)
Vancomycin ≥32b ≤1 —
NA, not available; ND, not determined; —, no gene was detected.
aResistance breakpoints were those recommended for Staphylococcus spp. in the CLSI Informational Supplement M100-S20 (www.clsi.org), except
for streptomycin, for which the breakpoint from the French Society for Microbiology (www.sfm.asso.fr) was used.
bThis breakpoint is applicable to CoNS.
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Staphylococcus belonging to the Staphylococcus intermedius
group (SIG) using the ID 32 STAPH system (bioMe´rieux, Marcy
l’E´toile, France) and disc diffusion susceptibility testing (Oxoid
Ltd, Basingstoke, UK). Based on these results, a local treatment
with fusidic acid gauze and application of 2% mupirocin oint-
ment four times a day for 8 days followed by a topical glucocor-
ticoid/antibiotic combination therapy (0.5 mg/g fluocinonide,
2.5 mg/g neomycin, 0.25 mg/g gramicidin and 100000 IU/g nys-
tatin) packing for 4 days improved the local condition. Six weeks
after the purulent infection, the wound had healed with scarring
and no bacterium was detectable in a repeat smear. Local
follow-up treatment with steroids and routine check-ups con-
firmed the absence of residual infection.
The multidrug-resistant Staphylococcus isolate was further
identified as MRSP ST71-t02-J containing SCCmec II–III using
MLST typing, spa typing, PFGE and SCCmec typing methods
described previously.1 MICs of antibiotics were determined in
Mueller–Hinton broth using custom Sensititre susceptibility
NLV73 plates (Trek Diagnostics System, East Grinstead, UK)
except for rifampicin, trimethoprim, kanamycin and fusidic acid,
which were tested using home-made microbroth dilution plates.
Antibiotic resistance genes were detected using a microarray.6
Mutations in topoisomerase genes gyrA and grlA were identified
by sequencing of PCR products7 (Table 1). The isolate was suscep-
tible to the antibiotics amikacin, chloramphenicol, fusidic acid,
linezolid, nitrofurantoin, the combination quinupristin/dalfopristin,
rifampicin and vancomycin (Table 1).
The patient owned a male dog that needed home care
because of various clinical problems such as diabetes, recurrent
warts and abdominal tumour. The dog had consultations in
various clinics and underwent several antibiotic treatments
(details of substances could not be ascertained). The dog was
euthanized before samples could be taken to determine
whether it was a carrier of the strain. The patient also owned
horses and cats; all of them were in good health without clinical
signs. Even if the ultimate source of the MRSP infection could not
be identified, the patient was infected with the same MRSP clone
(ST71-t02-J with SCCmec II–III) that has been disseminating in
dogs over Europe in recent years.1
A case similar to the one reported here has been described in the
USA, where a woman developed sinusitis caused by a methicillin-
resistant SIG whose origin could be attributed to her pet dog.8 In
that case, vancomycin and linezolid were used for treatment.
The increasing number of dogs carrying MRSP constitutes a
risk for pet owners to become colonized with MRSP, and MRSP
infections in humans may also increase in the near future. It is
therefore important to recognize MRSP as a zoonotic pathogen
and have antibiotics available for the treatment of MRSP infec-
tions in humans. Therefore, antibiotics such as mupirocin, linezo-
lid, quinupristin/dalfopristin, rifampicin and vancomycin that are
used for decolonization or as ‘last resort antibiotics’ against
methicillin-resistant staphylococci in humans should not be
used for treatment in animals.
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